FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 151 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Boy Shaves Head To Support Friend Going Through Cancer October 1, 2021 Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear... March 4, 2025 DeFi Trial: Smart Design and Impressive Results For the Benefit of... September 10, 2022 FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer May 25, 2021 Load more HOT NEWS Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade... Dormant Tumor Cells Can Be Sensitized to Chemotherapy AI is impacting cancer care, but also the environment Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers
